Published in Cancer Weekly, February 10th, 2009
"We sought to determine whether proteasome inhibition using bortezomib would prevent human CTR1 (hCTR1) degradation and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.